Ionis shares fell 21.4% after earnings, with the clearest disappointment being TRYNGOLZA’s slower-than-expected launch ramp: the company cut its 2026 revenue guidance for the drug to approximately $50 million. Management cited the time needed to establish a new treatment approach and said it is adjusting launch execution.
- Ionis lowered TRYNGOLZA’s 2026 full-year revenue guidance to approximately $50 million, reflecting a more gradual launch ramp than anticipated.
- By the end of September, about 1,500 prescribers had prescribed TRYNGOLZA for sHTG; approximately 24% had written more than one prescription.
- Management said most early prescriptions required a medical exception and described efforts to broaden the prescriber base, encourage repeat prescribing, and streamline the path from prescription to treatment.
- The company said it remains on track to meet full-year 2026 guidance for total revenue, operating loss, and cash; it also maintained confidence in DAWNZERA’s 2026 sales guidance.
- Ionis highlighted positive Phase III results for Sefaxersen in IgA nephropathy and ulefnersen in FUS-ALS, while acknowledging that two recent Phase III readouts did not deliver the outcomes it had hoped for.
Community Discussion